Business Wire

NC-LENOVO

15.2.2024 15:01:34 CET | Business Wire | Press release

Share
Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment

Today, Lenovo™ announced a strategic partnership with Anaconda® Inc., the leading provider of the world’s most popular artificial intelligence (AI), machine learning (ML) and data science platform, to empower Lenovo’s high performance data science workstations. The partnership will couple Lenovo’s trusted ThinkStation and ThinkPad workstation product portfolio heritage and leadership with Anaconda’s enterprise strengths for open-source leadership, security, and reliability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215334255/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment (Photo: Business Wire)

The rapidly evolving world of artificial intelligence, deep learning and generative AI is opening up new opportunities for businesses and data scientists. Much of the AI innovation taking place today is driven by open-source software and cloud-based solutions, with Python being a leading software language for AI applications. However, the data security risks associated with utilizing open-source software at an enterprise level, privacy concerns and often prohibitive cost of cloud-based AI solutions, is causing many organizations to rethink their approach to investment in AI development. With Intel®-powered Lenovo workstations architected with the latest generations of professional NVIDIA® GPUs built for large-language model fine-tuning, and the Anaconda Navigator’s ability to enable businesses to leverage open-source and AI with enhanced security, scale, and governance mechanisms in place, the partnership allows data scientists to create and deploy AI solutions with first class hardware and enterprise-grade AI software support within a more manageable investment framework.

Optimized for Intel platforms, Lenovo’s new generation of data science workstations deliver remarkable AI performance and is one of the world’s most powerful and scalable AI workstation portfolios. Planning for AI projects requires clear and thoughtful pathways to allocate the right hardware, software and skillsets to manage each stage of AI development. Lenovo workstations complement cloud-based AI solutions by acting as a bridge between local and cloud resources and aid data scientist flexibility and productivity. Lenovo’s full workstation portfolio includes highly configurable systems designed for nearly every AI workflow, industry or vertical, size and price point – all architected to drive the future of AI forward in an agile and cost-efficient way. From single CPU and GPU mobile workstations that are ideal for data input, collection and preparation, to the most powerful dual CPU and four GPU configurations for advanced AI workflows, Lenovo workstations with Anaconda Navigator offer protected “sandbox” environments to tackle the most complex AI solution development and deployment.

“With Lenovo’s trusted workstation leadership and Anaconda’s trusted leadership in open-source software support and reliability, the partnership is a perfect match,” said Rob Herman, Vice President and General Manager, Workstation and Client AI Group at Lenovo. “We’re excited to activate this partnership to aid data scientists in pushing forward the capabilities of AI with our premium workstations portfolio and Anaconda’s stellar open-source packages and repositories.”

Anaconda Navigator is available for download to use on current and future generation Lenovo Workstations.

“As artificial intelligence and machine learning models grow increasingly complex, high-performance workstations are imperative to empower data scientists with advanced capabilities,” said Chandler Vaughn, Chief Product Officer at Anaconda. “Lenovo's leadership in supplying optimized workstations, featuring robust GPUs, memory, and storage, positions them as an ideal collaborator for Anaconda and our Navigator desktop product. By jointly providing resilient hardware and trusted software tools, Lenovo and Anaconda present data scientists, AI developers, and AI engineers an unrivaled platform to freely explore emerging techniques in AI/ML. This symbiotic relationship enables organizations to push boundaries and accelerate innovations in artificial intelligence without technological constraints.”

For more information about Lenovo’s workstation portfolio, visit www.lenovo.com/workstations.

About Lenovo

Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

About Anaconda

With more than 45 million users, Anaconda is the most popular operating system for AI providing access to the foundational open-source Python packages used in modern AI, data science and machine learning through a seamless platform. We pioneered the use of Python for data science, championed its vibrant community, and continue to steward open-source projects that make tomorrow’s innovations possible. Our enterprise-grade solutions enable corporate, research, and academic institutions around the world to harness the power of open-source for competitive advantage, groundbreaking research, and a better world. To learn more visit anaconda.com or connect on Twitter or LinkedIn.

LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. Anaconda is a registered trademark owned by Anaconda, Inc. Intel is a trademark of Intel Corporation or its subsidiaries in the U.S. and/or other countries. NVIDIA is a trademark of NVIDIA Corporation. Inc. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215334255/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye